Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
modulates neurotransmitter release
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Allergan
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-181
|
| gptkbp:indication |
gptkb:psychologist
gptkb:attention_deficit_hyperactivity_disorder_(ADHD) schizophrenia |
| gptkbp:ingredients |
C20 H24 N2 O2
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of cognitive disorders
|
| gptkbp:manager |
oral
|
| gptkbp:side_effect |
dizziness
headache nausea insomnia |
| gptkbp:targets |
gptkb:Nicotinic_acetylcholine_receptor
|
| gptkbp:year_created |
gptkb:2010
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|